Critical Quality Attributes for Monoclonal Antibodies

Similar documents
Considerations in Setting Specifications

What to control? CQAs and CPPs

Risk-Based Change Management Using QbD Principles

Regulations for Handling Samples and Laboratory Testing from R&D through Phase III Clinical Trials

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1)

Scientific Challenges for Development of Biosimilar Monoclonal Antibodies. Rafiqul Islam Director, Global Bioanalytical Services Celerion

ASMS Regulated Bioanalysis Interest Group (RBIG) Workshop. Antibody-Drug Conjugates (ADC) A Complex Problem in Regulated Bioanalysis.

How To Write A Clinical Study On A Biosimilar Mab

Immunogenicity & Biotherapeutic Development

WHO guideline for abbreviated licensing pathways for certain biological therapeutic products

Guidance for Industry

ICH Topic Q 5 E Comparability of Biotechnological/Biological Products

Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use.

Workshop B Control Strategy

BIOSIMILARS A COMPLETE DEVELOPMENT PLATFORM

Post-Approval Change Management: Challenges and Opportunities An FDA Perspective

Sundar Ramanan, PhD, USA

Non-clinical development of biologics

RADIOPHARMACEUTICALS BASED ON MONOCLONAL ANTIBODIES

Guidance for Industry

Testing Services for Large Molecule Drug Development

Achieving Regulatory Success: Areas of focus for biotechnology companies. Michael J. Schlosser, PhD, DABT April 21, 2013

GUIDELINES ON EVALUATION OF SIMILAR BIOTHERAPEUTIC PRODUCTS (SBPs)

Quality by Design Application and Perspectives for biologicals. K. Ho, CHMP Biologics Working Party

Process Validation: Practical Aspects of the New FDA Guidance

Overview of Phase 1 Oncology Trials of Biologic Therapeutics

NONCLINICAL EVALUATION FOR ANTICANCER PHARMACEUTICALS

Process Performance Qualification. Demonstrating a High Degree of Assurance in Stage 2 of the Process Validation Lifecycle

A Risk Assessment of Pre-Licensure Manufacturing Changes

Guidance for Industry

Monoclonal Antibodies and Related Products Quality Guideline

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS

3 months 1.5 months 1.5 months. 1 month

TGN 1412 Welche Änderungen haben sich für die Erstanwendung am Menschen aus Sicht des BfArM ergeben?

MAB Solut. MABSolys Génopole Campus 1 5 rue Henri Desbruères Evry Cedex. is involved at each stage of your project

Overview of Drug Development: the Regulatory Process

ICH Topic S 1 A The Need for Carcinogenicity Studies of Pharmaceuticals. Step 5

EBE Position paper on labelling of biosimilars Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL)- draft April 2013

A FDA Perspective on Nanomedicine Current Initiatives in the US

How To Ensure Biosimilarity

PHARMACEUTICAL DEVELOPMENT

Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues

Accelerated Stability During Formulation Development of Early Stage Protein Therapeutics Pros and Cons of Contrasting Approaches

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE S1A. Current Step 4 version

Biological importance of metabolites. Safety and efficacy aspects

Making the switch to a safer CAR-T cell therapy

Technology Transfer of CMC Activities for MAb Manufacturing ge healthcare (

Thermo Scientific PepFinder Software A New Paradigm for Peptide Mapping

Towards Well-Defined ADCs (Antibody Drug Conjugates)

ICH guideline Q11 on development and manufacture of drug substances (chemical entities and biotechnological/ biological entities)

IMPURITIES IN NEW DRUG PRODUCTS

Guideline on similar biological medicinal products containing interferon beta

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Product Development Services for Global Registration of Drugs & Biologics th April Contact: kevin.breesch@toxikon.be

Quality by Design (QbD) Overview

EMABling Antibody Production Platform

Quality by Design Approaches to Analytical Methods -- FDA Perspective. Yubing Tang, Ph.D. FDA/CDER/ONDQA AAPS, Washington DC October 25, 2011

Lead optimization services

Valentina Gualato, Ph.D. Process Development Scientist

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE E15

Biopharmaceutical Process Evaluated for Viral Clearance

DMPK: Experimentation & Data

Workshop A Design Space (DS)

Guidance for Industry Safety Testing of Drug Metabolites

Call 2014: High throughput screening of therapeutic molecules and rare diseases

Challenges in early clinical development of biologics

Accelerating Antibody Drug Development Using Novel ADCC Reporter Bioassays. Terry Surowy, PhD Research Manager

Working with ICH Quality Guidelines - the Canadian Perspective

ICH M3 (R2) Guideline on Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals

Biotherapeutics Drug Development

Retrospective Analysis of a Host Cell Protein Perfect Storm: Identifying Immunogenic Proteins and Fixing the Problem

Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues

Biosimilars: Additional Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009

4.1 Objectives of Clinical Trial Assessment

The Effective Management of Change Across the ICHQ10 Lifecycle

WHITE PAPER. Developing Biosimilars in Emerging Markets: Regulatory and Clinical Considerations

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE Q6B. Current Step 4 version

The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence

Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues

Bispecific antibodies with native chain structure

Rare Diseases: Common Issues in Drug Development Guidance for Industry

Exciting Trends in Bioprocessing

ENDORSED BY THE GOVERNANCE COMMITTEE

Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant erythropoietins (Revision)

New HLA class I epitopes defined by murine monoclonal antibodies

Optimal Conditions for F(ab ) 2 Antibody Fragment Production from Mouse IgG2a

Pharmacology skills for drug discovery. Why is pharmacology important?

Guideline on similar biological medicinal products containing interferon beta

Benefits and Challenges of Change Protocol Approach: An EU Agency Perspective

Anti-CD38 anti-cd3 bispecific antibody in multiple myeloma

M4E(R2): The CTD Efficacy

Session 6 Clinical Trial Assessment Phase I Clinical Trial

Introduction to Bioprocessing

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE

DARATUMUMAB, A CD38 MONOCLONAL ANTIBODY IN PATIENTS WITH MULTIPLE MYELOMA - DATA FROM A DOSE- ESCALATION PHASE I/II STUDY

Workshop on process validation

Literature Review: CHO versus HEK Cell Glycosylation

Transcription:

Critical Quality Attributes for Monoclonal Antibodies Reed J. Harris Protein Analytical Chemistry Dept. Genentech, Inc. South San Francisco, CA 94080 USA

Acknowledgements Gail Burnett Stephen Gomez Amita Joshi Yung-Hsiang Kao Lynne Krummen Paul Motchnik Wassim Nashabeh Valerie Quarmby Ron Taticek and many others!

Definition Critical Quality Attribute: A physical, chemical, biological or microbiological property or characteristic that should be within an appropriate limit, range, or distribution to ensure the desired product quality. [ICH Q8 R1]

Quality by Design concepts Historical ranges Regulatory precedents Target product profile Control space Patient impact Specifications Scientific knowledge Process capabilities Critical process parameters Clinical experience Design space

Defining Critical Quality Attributes Historical ranges Regulatory precedents Target product profile Control space Patient impact Specifications Scientific knowledge Process capabilities Critical process parameters Clinical experience Design space

CQA Assessments 1. What is the potential impact to patients when high or low levels of a variant or impurity are present? - Impact: 2 20 points - Four impact aspects to consider: * Biological activity * Immunogenicity * Pharmacokinetics * Safety 2. How certain are we about question #1? - Uncertainty: 1 7 points Combine as a risk ranking & filtering assessment Assessment will need to reflect route of administration, patient class, therapeutic window etc. Assigning CQAs is independent of: - historical ranges - our ability to control their levels

Impact Definitions: Biological Activity Impact & Rating Very High (20) High (16) Moderate (12) Low (4) None (2) Biological Activity >100% change 40-100% change 20-40% change <20% change No change Consider: Loss of potency for isolated forms Certain forms may be superpotent - afucosylated anti-cd20s - aggregates

Impact Definitions: Pharmacokinetics Impact & Rating Very High (20) High (16) Moderate (12) Low (4) None (2) Pharmacokinetic Effects >40% change on PK 20-40% change with impact on PD 20-40% change with no impact on PD <20% change with no impact on PD No impact on PK or PD Consider: PK: Area Under Curve (AUC) PD: if available Example: Fc glycans - unlike many glycoprotein types, common IgG1 Fc glycans do not affect clearance Example: charge variants - impact of charge variation on clearance is well-documented - do small pi differences matter? - AUC of acidic variants matched the main form for one IgG1

Impact Definitions: Immunogenicity Impact & Rating Very High (20) High (16) Moderate (12) Low (4) None (2) Immunogenicity ATA detected & confers limits on safety ATA detected & confers limits on efficacy ATA detected with in vivo manageable effect ATA detected with minimal in vivo effect ATA not detected or ATA detected with no relevant in vivo effect ATA: anti-therapeutic antibodies Consider: prior to clinical studies, variants also present on plasma-derived IgG may be presumed low risk - deamidated Fc -glycated - loss of C-terminal Lys clinical experience is needed to make the final assessment

Impact Definitions: Safety Impact & Rating Very High (20) High (16) Moderate (12) Low (4) None (2) Safety (Potential or Observed) Irreversible AEs Reversible AEs Manageable AEs Minor, transient AEs No AEs Consider: Safety effects linked to specific characteristics are going to be rare Examples: 1. Complement-dependent cytotoxicity (infusion reactions). 2. Gal(α1-3Gal) on cetuximab Fab glycans (anaphylaxis)

Uncertainty Scale Rating Uncertainty Description (Variants and Host Impurities) Description (Process Raw Materials) 7 Very High No information (new variant) No information (new) 5 High 3 Moderate Published external literature for variant in related molecule. Nonclinical or in vitro data with this molecule. Data (nonclinical, in vitro or clinical) from a similar molecule class. Component is used in other Genentech processes 2 Low Variant has been present in material used in clinical trials. 1 Very Low Impact of specific variant established in clinical studies with this molecule. GRAS or studied in clinical trials

CQAs assigned based on severity score Low Uncertainty High 1 2 3 5 7 Low Impact High 20 20 40 60 100 140 16 16 32 48 80 112 12 12 24 36 60 84 4 4 8 12 20 28 2 2 4 6 10 14 >13 = Critical Quality Attribute <13 = Not a CQA

Impact Definitions Impact & Rating Biological Activity PK / PD Immunogenicity Safety Very High (20) High (16) >100% change 40-100% change >40% change on PK 20-40% change with impact on PD ATA detected & confers limits on safety ATA detected & confers limits on efficacy Irreversible AEs Reversible AEs CQA Moderate (12) 20-40% change 20-40% change with no impact on PD ATA detected with manageable in vivo effect Manageable AEs Low (4) <20% change <20% change with no impact on PD ATA detected with minimal in vivo effect Minor, transient AEs None (2) No change No impact on PK or PD ATA not detected or ATA detected with no relevant in vivo effect No AEs no reduced uncertainty will move a high-impact attribute to a non-cqa range severity rating is based on highest relevant impact

Lifecycle Presumptive CQAs: pre-ind period - identify unusual attributes to be controlled - internal discussion - focus attention on high impact or high uncertainty attributes; target these for further study Refined CQAs: end of Phase II - to guide process characterization study design - review with health authorities at end-of-phase II meetings Final CQAs: licensing and post-approval - guide control strategy decisions (testing or validation) - may be updated with new information

Control of CQAs CQAs Control by testing Specifications: IPC, release, stability Quality attributes CQA Assessment Process control Process characterization, validation Not CQAs Characterization, comparability assessments, other monitoring

CQA decision points under development CQAs Control by testing Specifications: IPC, release, stability Quality attributes CQA Assessment Process control Process characterization, validation ready to apply Not CQAs Characterization, comparability assessments, other monitoring

Summary CQAs are based on patient impact (2 20 points) and uncertainty (1 7 points), not on process capabilities or historical ranges - biological activity - pharmacokinetics / PD - immunogenicity -safety Application of CQAs changes during development - scientific understanding - guide process characterization / CPPs - establish control strategy Control CQAs by testing (specs) or process control Strategy may need refinement based on experience

Challenge CQA / QBD approach may change how we control MAb products Can we ever eliminate certain automatic types of testing, if justified by our CQA assessment? Example: charge variants may be deemed non-cqas by our analysis. Would the health authorities accept a control system without a chargebased method? All parties need to be committed to this approach, wherever it leads Thank you!